Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Recommendation of “Hold” by Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has received an average rating of “Hold” from the seven brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $6.2333.

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Friday, July 24th.

Insider Activity

In related news, Director Julie Mchugh sold 21,571 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total value of $80,459.83. Following the completion of the sale, the director directly owned 250,749 shares of the company’s stock, valued at approximately $935,293.77. This represents a 7.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ronald Silver sold 127,890 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the sale, the insider owned 313,680 shares of the company’s stock, valued at $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 9.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Pacer Advisors Inc. purchased a new position in Ironwood Pharmaceuticals during the first quarter valued at approximately $3,982,000. Segall Bryant & Hamill LLC purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter worth approximately $976,000. Bull Harbor Capital LLC purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter worth approximately $48,000. EverSource Wealth Advisors LLC boosted its stake in shares of Ironwood Pharmaceuticals by 48.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 20,336 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 6,656 shares during the period. Finally, Quantinno Capital Management LP boosted its stake in shares of Ironwood Pharmaceuticals by 9.1% during the 1st quarter. Quantinno Capital Management LP now owns 129,703 shares of the biotechnology company’s stock valued at $455,000 after buying an additional 10,810 shares during the period.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $4.15 on Thursday. The company has a 50-day moving average of $3.87 and a two-hundred day moving average of $3.97. The stock has a market cap of $676.70 million, a price-to-earnings ratio of 6.92 and a beta of 0.20. Ironwood Pharmaceuticals has a one year low of $0.80 and a one year high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $113.04 million for the quarter, compared to analyst estimates of $114.84 million. Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. Analysts anticipate that Ironwood Pharmaceuticals will post 1.04 earnings per share for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.